← Back to results

Clin Transl Med · 2021

A CRISPR/CAS9-based strategy targets the personalized chimeric neosequence in fusion-driven cancer genome for precision medicine.

Clinical and translational medicine, 11(3): e355 PMID 33783997 DOI 10.1002/ctm2.355

Open in PubMed ↗ Open via DOI ↗

Abstract

This article has no abstract in PubMed.

Cite